A TLR antagonist comprising an immuno-regulatory oligonucleotide compound (IRO) that is an antagonist for one or more TLR having the structure in which: CG is an oligonucleotide moiety that is CpG, C * pG, C * pG * or CpG *, in which C is cytosine, C * is a pyrimidine nucleotide derivative that is a pyrimidine nucleotide that has a base that is not cytosine, thymine or uracil and / or a sugar that is not ribose or 2'- deoxyribose and may be present in the nucleus of an oligonucleotide, G is guanosine, and G * is a purine nucleotide derivative that is a purine nucleotide that has a base that is not guanine or adenine and / or a sugar that is not ribose or 2'-deoxyribose and may be present in the nucleus of an oligonucleotide； N1-N3, at each occurrence, is independently i) a nucleotide, ii) a nucleotide derivative that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine or uracil and / or a sugar which is not ribose or 2'-deoxyribose and may be present in the nucleus of an oligonucleotide, or iii) a non-nucleotide junction, provided that at least one of N1-N3 is a nucleotide derivative or non-nucleotide junction that suppresses activity of the oligonucleotide moiety； N1-N3, at each occurrence, is independently i) a nucleotide, or ii) a nucleotide derivative that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine or uracil and / or a sugar that is not ribose or 2'-deoxyribose and may be present in the nucleus of an oligonucleotide； Nm and Nm, at each occurrence, is independently a nucleotide, a nucleotide derivative that is a purine or pyrimidine nucleotide that has a base that is not guanine, cytosine, adenine, thymine or uracil and / or a sugar that is not ribose or 2'-deoxyribose and may be present in the nucleus of an oligonucleotide, or non-nucleotide junction； and also provided that the compound contains less than 3 consecutive guanosine nucleotides； in which the re
